The UK Joint Committee for Vaccination and Immunization (JCVI) has not so far decided to extend HPV vaccination to boys, but this possibility remains under consideration (Public Health England Guidance on HPV 2014-15). The potential benefit of protecting males from face and neck cancer will be an important consideration, both in the UK and in […]
Category: HPV vaccination
Population-based evidence for the preventative efficacy of quadrivalent HPV in Australia
The HPV vaccination programmes introduced by many countries over the last few years (since 2007) reveal considerable diversity in the coverage they have achieved, the mode of access (i.e. school, public health, private clinics) and responsibility for cost (i.e. publically vv. privately funded) – even in Europe (see ECDC Guidance). In the light of the […]
Missed HPV vaccination opportunities: a consequence of avoiding awkward conversations
In the US, routine administration of quadrivalent HPV vaccine is recommended for girls and boys at 11-12 yrs, with catch-up vaccination recommended up to 26 yrs for girls, and 21 yrs for boys. The difficulty has been in the implementation of the recommendation: overall rates of initiating and completion among US teenage girls currently stand […]
“Catch-up” and incomplete HPV vaccination better than nothing
Quadrivalent HPV vaccine (HPV4) has been shown to protect against HPV types 16 & 18, which cause 70% of cervical cancers, and HPV types 6 & 11, which cause 90% of genital warts. Health authorities in the US and elsewhere have therefore recommended routine vaccination of girls (and more recently boys) at ages 11 & […]